Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

June 01, 2026 08:30 ET | Source: Oak Hill Bio

Oak Hill Bio Raises $32.5 Million Series A Financing to Advance Antisense Oligonucleotide Therapy Rugonersen to Phase 3 Study in Angelman Syndrome

Series A financing co-led by Balyasny Asset Management, venBio, and Janus Henderson InvestorsRugonersen, a potentially best-in-class antisense oligonucleotide (ASO) therapy for Angelman syndrome, is...